197 related articles for article (PubMed ID: 9892854)
1. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol.
Nagamoto HT; Adler LE; McRae KA; Huettl P; Cawthra E; Gerhardt G; Hea R; Griffith J
Neuropsychobiology; 1999; 39(1):10-7. PubMed ID: 9892854
[TBL] [Abstract][Full Text] [Related]
2. Gating of auditory P50 in schizophrenics: unique effects of clozapine.
Nagamoto HT; Adler LE; Hea RA; Griffith JM; McRae KA; Freedman R
Biol Psychiatry; 1996 Aug; 40(3):181-8. PubMed ID: 8830951
[TBL] [Abstract][Full Text] [Related]
3. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.
Adler LE; Olincy A; Cawthra EM; McRae KA; Harris JG; Nagamoto HT; Waldo MC; Hall MH; Bowles A; Woodward L; Ross RG; Freedman R
Am J Psychiatry; 2004 Oct; 161(10):1822-8. PubMed ID: 15465979
[TBL] [Abstract][Full Text] [Related]
4. Auditory sensory gating and catecholamine metabolism in schizophrenic and normal subjects.
Waldo M; Gerhardt G; Baker N; Drebing C; Adler L; Freedman R
Psychiatry Res; 1992 Oct; 44(1):21-32. PubMed ID: 1461944
[TBL] [Abstract][Full Text] [Related]
5. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.
Hong X; Chan RC; Zhuang X; Jiang T; Wan X; Wang J; Xiao B; Zhou H; Jiang L; Weng B
Schizophr Res; 2009 Mar; 108(1-3):151-7. PubMed ID: 19106034
[TBL] [Abstract][Full Text] [Related]
6. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
Light GA; Geyer MA; Clementz BA; Cadenhead KS; Braff DL
Am J Psychiatry; 2000 May; 157(5):767-71. PubMed ID: 10784470
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.
Moxon KA; Gerhardt GA; Adler LE
Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485
[TBL] [Abstract][Full Text] [Related]
8. P50 gating in deficit and nondeficit schizophrenia.
Santos JL; Sánchez-Morla EM; Aparicio A; García-Jiménez MA; Villanueva C; Martínez-Vizcaíno V; Arango C
Schizophr Res; 2010 Jun; 119(1-3):183-90. PubMed ID: 20153607
[TBL] [Abstract][Full Text] [Related]
9. Effects of clozapine on perceptual abnormalities and sensory gating: a preliminary cross-sectional study in schizophrenia.
Micoulaud-Franchi JA; Aramaki M; Geoffroy PA; Richieri R; Cermolacce M; Faget C; Ystad S; Kronland-Martinet R; Lancon C; Vion-Dury J
J Clin Psychopharmacol; 2015 Apr; 35(2):184-7. PubMed ID: 25587694
[TBL] [Abstract][Full Text] [Related]
10. Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia.
Becker J; Gomes I; Ghisolfi ES; Schuch A; Ramos FL; Ehlers JA; Nora DB; Lara DR; da Costa JC
Clin Neurophysiol; 2004 Feb; 115(2):396-401. PubMed ID: 14744582
[TBL] [Abstract][Full Text] [Related]
11. Clozapine response and plasma catecholamines and their metabolites.
Green AI; Alam MY; Sobieraj JT; Pappalardo KM; Waternaux C; Salzman C; Schatzberg AF; Schildkraut JJ
Psychiatry Res; 1993 Feb; 46(2):139-49. PubMed ID: 8483973
[TBL] [Abstract][Full Text] [Related]
12. Plasma free 3-methoxy-4-hydroxyphenylglycol in acute schizophrenics before and after treatment.
Kaneko M; Honda K; Kanno T; Horikoshi R; Manome T; Watanabe A; Kumashiro H
Neuropsychobiology; 1992; 25(3):126-9. PubMed ID: 1357582
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic effects on auditory sensory gating in schizophrenia patients.
Sánchez-Morla EM; Santos JL; Aparicio A; García-Jiménez MA; Villanueva C; Martínez-Vizcaíno V; Arango C
Eur Neuropsychopharmacol; 2009 Dec; 19(12):905-9. PubMed ID: 19833483
[TBL] [Abstract][Full Text] [Related]
14. Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine.
Hatzimanolis J; Lykouras L; Markianos M; Oulis P
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1077-85. PubMed ID: 9829289
[TBL] [Abstract][Full Text] [Related]
15. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
Brown AS; Gewirtz G; Harkavy-Friedman J; Cooper T; Brébion G; Amador XF; Malaspina D; Gorman JM
Neuropsychopharmacology; 1997 Nov; 17(5):317-25. PubMed ID: 9348547
[TBL] [Abstract][Full Text] [Related]
16. Sensory gating deficits in psychiatric inpatients: relation to catecholamine metabolites in different diagnostic groups.
Baker NJ; Staunton M; Adler LE; Gerhardt GA; Drebing C; Waldo M; Nagamoto H; Freedman R
Biol Psychiatry; 1990 Mar; 27(5):519-28. PubMed ID: 2310807
[TBL] [Abstract][Full Text] [Related]
17. Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings.
Waldo MC; Cawthra E; Adler LE; Dubester S; Staunton M; Nagamoto H; Baker N; Madison A; Simon J; Scherzinger A
Schizophr Res; 1994 May; 12(2):93-106. PubMed ID: 8043530
[TBL] [Abstract][Full Text] [Related]
18. [Effect of clozapine on biogenic amines within the scope of drug treatment of schizophrenic psychoses in adolescence].
Schulz E; Remschmidt H; Fleischhaker C
Z Kinder Jugendpsychiatr; 1994 Dec; 22(4):285-98. PubMed ID: 7856324
[TBL] [Abstract][Full Text] [Related]
19. P50 gating at acute and post-acute phases of first-episode schizophrenia.
Devrim-Uçok M; Keskin-Ergen HY; Uçok A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1952-6. PubMed ID: 18929611
[TBL] [Abstract][Full Text] [Related]
20. P50 sensory gating in adolescents from a pacific island isolate with elevated risk for schizophrenia.
Myles-Worsley M; Ord L; Blailes F; Ngiralmau H; Freedman R
Biol Psychiatry; 2004 Apr; 55(7):663-7. PubMed ID: 15038993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
